Seattle Genetics cancer drug price may top $100,000
(Reuters)
<p>WASHINGTON (Reuters) ? The price of Seattle Genetics Inc’s blood cancer drug Adcetris could top $100,000 for a course of treatment, becoming the latest cancer medicine to come at a high cost.</p> <p> The U.S. Food and Drug Administration on Friday gave its nod to Adcetris, the first drug specifically indicated for anaplastic large cell lymphoma (ALCL) and the first one approved for Hodgkin’s lymphoma since 1977.</p> <p> Seattle Genetics on Monday said the drug will cost $4,500 per vial. In its clinical trials, the company said, patients on average received three vials per dose and between seven and nine doses per treatment.</p> <p> The total price would then generally vary from $94,500 to $121,500 per patient, within Wall Street’s expected range.</p> <p> The drugmaker’s shares were down 2.3 percent to $14.70 in afternoon trading on Nasdaq, underperforming the Nasdaq Biotech index, which was down 0.3 percent.</p> <p> “Seattle Genetics’ decision to price Adcetris north of $100,000 see
Seattle Genetics cancer drug price may top $100,000
(Reuters) <p>WASHINGTON (Reuters) ? The price of Seattle Genetics Inc’s blood cancer drug Adcetris could top $100,000 for a course of treatment, becoming the latest cancer medicine to come at a high cost.</p> <p> The U.S. Food and Drug Administration on Friday gave its nod to Adcetris, the first drug specifically indicated for anaplastic large cell lymphoma (ALCL) and the first one approved for Hodgkin’s lymphoma since 1977.</p> <p> Seattle Genetics on Monday said the drug will cost $4,500 per vial. In its clinical trials, the company said, patients on average received three vials per dose and between seven and nine doses per treatment.</p> <p> The total price would then generally vary from $94,500 to $121,500 per patient, within Wall Street’s expected range.</p> <p> The drugmaker’s shares were down 2.3 percent to $14.70 in afternoon trading on Nasdaq, underperforming the Nasdaq Biotech index, which was down 0.3 percent.</p> <p> “Seattle Genetics’ decision to price Adcetris north of $100,000 see
Seattle Genetics cancer drug price may top $100,000
(Reuters) <p>WASHINGTON (Reuters) ? The price of Seattle Genetics Inc’s blood cancer drug Adcetris could top $100,000 for a course of treatment, becoming the latest cancer medicine to come at a high cost.</p> <p> The U.S. Food and Drug Administration on Friday gave its nod to Adcetris, the first drug specifically indicated for anaplastic large cell lymphoma (ALCL) and the first one approved for Hodgkin’s lymphoma since 1977.</p> <p> Seattle Genetics on Monday said the drug will cost $4,500 per vial. In its clinical trials, the company said, patients on average received three vials per dose and between seven and nine doses per treatment.</p> <p> The total price would then generally vary from $94,500 to $121,500 per patient, within Wall Street’s expected range.</p> <p> The drugmaker’s shares were down 2.3 percent to $14.70 in afternoon trading on Nasdaq, underperforming the Nasdaq Biotech index, which was down 0.3 percent.</p> <p> “Seattle Genetics’ decision to price Adcetris north of $100,000 see
Pops
Newest Clips
Latest Comments
Most Pops
Print
Save
Turn on live update